Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 28
Filtrar
1.
Int J Hematol ; 119(4): 407-415, 2024 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-38334914

RESUMEN

Age is a significant risk factor for ischemic stroke. However, the influence of aging on coagulation parameters in non-valvular atrial fibrillation (NVAF) patients treated with direct oral anticoagulants (DOACs) remains unclear. A total of 775 samples were collected from 224 NVAF patients receiving apixaban, edoxaban or rivaroxaban. The samples were categorized into three age groups: (i) ≤ 64 years, (ii) 65-74 years, and (iii) ≥ 75 years (apixaban: N = 48, 108, 119; edoxaban: N = 63, 68, 126; rivaroxaban: N = 115, 90, 38, respectively). Coagulation parameters including fibrinogen (Fbg), factor II, factor V, factor VII, factor X, and D-dimer, were compared between the three age groups for each drug. The slopes in the correlation between drug concentrations and modified diluted prothrombin time (mdPT) were also assessed. Fbg and factor V increased with age, while factor II and factor X decreased. Factor VII and D-dimer showed no significant differences across age categories. The slope in response to drug concentrations was similar between the age groups. In NVAF patients treated with apixaban, edoxaban and rivaroxaban, some coagulation parameters exhibited age-related variation. However, the response of mdPT to drug concentration was consistent across age categories.


Asunto(s)
Fibrilación Atrial , Piridinas , Accidente Cerebrovascular , Tiazoles , Humanos , Persona de Mediana Edad , Rivaroxabán/efectos adversos , Warfarina , Anticoagulantes , Hemorragia/tratamiento farmacológico , Accidente Cerebrovascular/etiología , Accidente Cerebrovascular/prevención & control , Fibrilación Atrial/complicaciones , Fibrilación Atrial/tratamiento farmacológico , Fibrilación Atrial/inducido químicamente , Dabigatrán/efectos adversos , Factor X/uso terapéutico , Factor VII/uso terapéutico , Protrombina , Factor V , Piridonas/uso terapéutico , Administración Oral
3.
J Dermatol ; 50(12): 1539-1549, 2023 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-37752738

RESUMEN

A previous, proof-of-concept clinical study suggested that dermal sheath cup cell injections into the affected areas of male/female pattern hair loss (PHL) may have some amelioratory effects, the clinical efficacy of which needs further examination. A phase III equivalent clinical study was conducted to further probe the therapeutic potential of this novel approach and verify its safety and efficacy in improving the appearance of PHL. Thirty-six participants with PHL were injected with dermal sheath cup cell harvested from non-affected occipital hair follicles twice in quarterly intervals. Global photographic assessment and phototrichogram were performed in a blinded manner. Patient-reported outcomes were assessed for 12 months. On global photographic assessment, 30% of the participants showed improvement. The analysis of phototricogram data detected the increases in the cumulative hair diameter, hair cross-sectional area, and mean hair diameter of 107.6 ± 152.6 µm/cm2 , 13069.1 ± 10960.7 µm2 /cm2 , and 0.9 ± 0.9 µm (ratios vs. baseline: +1.4%, +3.4%, and +2.2%), respectively. The female and high terminal hair ratio groups achieved better improvement. Of the total participants, 62.9% noted some degree of improvement. No serious adverse events were detected. This novel approach exhibited visible effects while ensuring safety and patient satisfaction. Therefore, it holds promise as a possible therapeutic option for treating PHL, especially in women.


Asunto(s)
Alopecia , Cabello , Femenino , Humanos , Masculino , Alopecia/cirugía , Trasplante de Células , Folículo Piloso , Resultado del Tratamiento
4.
Eur J Clin Pharmacol ; 79(12): 1623-1630, 2023 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-37740121

RESUMEN

PURPOSE: To assess the antiplatelet effect of cilostazol clinically, we compared the effects of cilostazol in combination with clopidogrel on various platelet function tests. METHODS: We recruited patients with ischemic stroke at high risk of recurrence who were treated with clopidogrel alone within 180 days after stroke onset. Subjects underwent baseline platelet function tests, and were then randomly assigned to receive dual antiplatelet therapy (DAPT) comprising clopidogrel and cilostazol or clopidogrel monotherapy (SAPT). After 6 months, platelet function was measured again and compared to that at baseline in each group, and the rate of change was compared between groups. RESULTS: Thirty-four patients were enrolled, but 4 patients were excluded for various reasons. In total, 30 subjects (13 in DAPT and 17 in SAPT group) were analyzed. Adenosine diphosphate- and collagen-induced aggregation, VerifyNow P2Y12 reaction units, vasodilator-stimulated phosphoprotein (platelet reactivity index: PRI) and plasma p-selectin concentration were significantly lower (P = 0.004, 0.042, 0.049, 0.003 and 0.006 respectively), while VerifyNow % inhibition was significantly higher at 6 months compared to baseline (P = 0.003) in the DAPT group only. Comparison of the rate of change in each parameter from baseline to 6 months showed that while PRI decreased at a greater rate (P = 0.012), VerifyNow % inhibition increased at a greater rate (P = 0.003) in the DAPT group than the SAPT group. CONCLUSIONS: The inhibitory effects of adjunctive cilostazol added to clopidogrel on platelet function differed by type of platelet function test. VerifyNow % inhibition and PRI were more inhibited than the other platelet function tests. TRIAL REGISTRATION: CSPS.com substudy in TWMU (UMIN000026672), registered on April 1, 2017. This study was performed as a substudy of CSPS.com (UMIN000012180, registered on October 31, 2013) and was retrospectively registered.


Asunto(s)
Inhibidores de Agregación Plaquetaria , Ticlopidina , Humanos , Clopidogrel/farmacología , Cilostazol/farmacología , Inhibidores de Agregación Plaquetaria/farmacología , Inhibidores de Agregación Plaquetaria/uso terapéutico , Ticlopidina/farmacología , Ticlopidina/uso terapéutico , Aspirina/farmacología , Aspirina/uso terapéutico , Tetrazoles/farmacología , Tetrazoles/uso terapéutico , Pruebas de Función Plaquetaria , Quimioterapia Combinada , Agregación Plaquetaria
5.
J Dermatol Sci ; 112(2): 92-98, 2023 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-37777361

RESUMEN

BACKGROUND: The efficacy of therapeutic modalities for hair disease can be evaluated globally by photo assessment and more precisely by phototrichogram (PTG). However, the latter procedure is laborious, time consuming, subject to inter-observer variation, and requires hair clipping. OBJECTIVE: To establish an automated and patient/investigator friendly methodology enabling quantitative hair amount evaluation for daily clinical practice. METHODS: A novel automated numerical algorithm (aNA) adopting digital image binarization (i.e., black and white color conversion) was invented to evaluate hair coverage and measure PTG parameters in scalp images. Step-by-step improvement of aNA was attempted through comparative analyses of the data obtained respectively by the novel approach and conventional PTG/global photography assessment (GPA). RESULTS: For measuring scalp hair coverage, the initial version of aNA generally agreed with the cumulative hair diameter as assessed using PTG, showing a coefficient of 0.60. However, these outcomes were influenced by the angle of hair near the parting line. By integrating an angle compensation formula, the standard deviation of aNA data decreased from 5.7% to 1.2%. Consequently, the coefficient of determination for hair coverage calculated using the modified aNA and cumulative hair diameter assessed by PTG increased to 0.90. Furthermore, the change in hair coverage as determined by the modified aNA protocol correlated well with changes in the GPA score of images obtained using clinical trials. CONCLUSION: The novel aNA method provides a valuable tool for enabling simple and accurate evaluation of hair growth and volume for clinical trials and for treatment of hair disease.


Asunto(s)
Enfermedades del Cabello , Cuero Cabelludo , Humanos , Alopecia , Invenciones , Cabello/diagnóstico por imagen , Fotograbar/métodos , Enfermedades del Cabello/diagnóstico por imagen
6.
Int J Lab Hematol ; 45(1): 119-125, 2023 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-36114152

RESUMEN

INTRODUCTION: A single assay to assess the effect of the direct FXa inhibitor is needed clinically because prothrombin (PT) assay is not yet sensitive enough for accurate evaluation. We developed modified diluted prothrombin time (mdPT) assay showing a high reactivity to direct FXa inhibitors based on prothrombin time (PT) reagent. The purpose of this study was to evaluate the reactivity of mdPT to direct FXa inhibitors comparing to that of commercial PT reagents and diluted prothrombin time (dPT). METHODS: The correlation and slopes of mdPT against the drug concentrations by anti-Xa assay were compared to those of the four commercial reagents of PT or dPT in 275, 257, and 243 clinical samples collected from non-valvular atrial fibrillation (NVAF) patients who are prescribed apixaban, edoxaban or rivaroxaban for stroke prevention, respectively. RESULTS: The correlation coefficient (95% confidence interval) of mdPT against apixaban, edoxaban, and rivaroxaban was 0.818 (0.775-0.854), 0.914 (0.892-0.932), and 0.814 (0.766-0.852), respectively. The slope (95% confidence interval) of mdPT for apixaban, edoxaban, and rivaroxaban was 0.0068 (0.0063-0.0075), 0.0076 (0.0072-0.0080), and 0.0072 (0.0065-0.0078), respectively, which were higher than that of four commercial PT and dPT reagents, ranging within 0.0006-0.0023, 0.0017-0.0038, and 0.0016-0.0057 (all, p < 0.001), respectively. CONCLUSION: Compared with other PT and dPT reagents, mdPT reagent showed sharper slope to all direct FXa inhibitors, and higher correlation to apixaban and comparable correlation to edoxaban and rivaroxaban. This new reagent is expected to be a coagulation screening assay having a consistently high response to any types of direct FXa inhibitors.


Asunto(s)
Fibrilación Atrial , Rivaroxabán , Humanos , Tiempo de Protrombina , Rivaroxabán/uso terapéutico , Fibrilación Atrial/tratamiento farmacológico , Inhibidores del Factor Xa , Piridonas/uso terapéutico , Anticoagulantes/uso terapéutico
8.
Biotechnol Bioeng ; 118(4): 1736-1749, 2021 04.
Artículo en Inglés | MEDLINE | ID: mdl-33501662

RESUMEN

The reconstructed in vitro translation system known as the PURE system has been used in a variety of cell-free experiments such as the expression of native and de novo proteins as well as various display methods to select for functional polypeptides. We developed a refined PURE-based display method for the preparation of stable messenger RNA (mRNA) and complementary DNA (cDNA)-peptide conjugates and validated its utility for in vitro selection. Our conjugate formation efficiency exceeded 40%, followed by gel purification to allow minimum carry-over of components from the translation system to the downstream assay enabling clean and efficient random peptide sequence screening. We chose the commercially available anti-FLAG M2 antibody as a target molecule for validation. Starting from approximately 1.7 × 1012 random sequences, a round-by-round high-throughput sequencing showed clear enrichment of the FLAG epitope DYKDDD as well as revealing consensus FLAG epitope motif DYK(D/L/N)(L/Y/D/N/F)D. Enrichment of core FLAG motifs lacking one of the four key residues (DYKxxD) indicates that Tyr (Y) and Lys (K) appear as the two key residues essential for binding. Furthermore, the comparison between mRNA display and cDNA display method resulted in overall similar performance with slightly higher enrichment for mRNA display. We also show that gel purification steps in the refined PURE-based display method improve conjugate formation efficiency and enhance the enrichment rate of FLAG epitope motifs in later rounds of selection especially for mRNA display. Overall, the generalized procedure and consistent performance of two different display methods achieved by the commercially available PURE system will be useful for future studies to explore the sequence and functional space of diverse polypeptides.


Asunto(s)
ADN Complementario/genética , Epítopos/genética , Secuenciación de Nucleótidos de Alto Rendimiento , Biblioteca de Péptidos , ARN Mensajero/genética , Humanos
9.
Case Rep Neurol ; 12(Suppl 1): 137-142, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-33505285

RESUMEN

Moyamoya disease is an uncommon vascular disease, which causes obstruction and stenosis of arteries of the circle of Willis, and preferentially affects children and young adults. This disease is seen across the world, but is more common in East Asia. It may cause hemorrhagic or ischemic stroke, or transient ischemic attack. If symptoms or cerebral blood flow become worse, revascularization surgery is recommended. We present 2 cases of moyamoya disease who underwent bypass surgery. We also discuss the epidemiology, pathology, genomics, and symptomatology as well as diagnosis, and management of moyamoya disease.

11.
Science ; 352(6281): 87-90, 2016 Apr 01.
Artículo en Inglés | MEDLINE | ID: mdl-27034372

RESUMEN

When animals encounter conflict they initiate and escalate aggression to establish and maintain a social hierarchy. The neural mechanisms by which animals resolve fighting behaviors to determine such social hierarchies remain unknown. We identified two subregions of the dorsal habenula (dHb) in zebrafish that antagonistically regulate the outcome of conflict. The losing experience reduced neural transmission in the lateral subregion of dHb (dHbL)-dorsal/intermediate interpeduncular nucleus (d/iIPN) circuit. Silencing of the dHbL or medial subregion of dHb (dHbM) caused a stronger predisposition to lose or win a fight, respectively. These results demonstrate that the dHbL and dHbM comprise a dual control system for conflict resolution of social aggression.


Asunto(s)
Agresión/fisiología , Conflicto Psicológico , Habénula/fisiología , Negociación , Animales , Jerarquia Social , Núcleo Interpeduncular/fisiología , Transmisión Sináptica , Pez Cebra
12.
Neuron ; 84(5): 1034-48, 2014 Dec 03.
Artículo en Inglés | MEDLINE | ID: mdl-25467985

RESUMEN

Anticipation of danger at first elicits panic in animals, but later it helps them to avoid the real threat adaptively. In zebrafish, as fish experience more and more danger, neurons in the ventral habenula (vHb) showed tonic increase in the activity to the presented cue and activated serotonergic neurons in the median raphe (MR). This neuronal activity could represent the expectation of a dangerous outcome and be used for comparison with a real outcome when the fish is learning how to escape from a dangerous to a safer environment. Indeed, inhibiting synaptic transmission from vHb to MR impaired adaptive avoidance learning, while panic behavior induced by classical fear conditioning remained intact. Furthermore, artificially triggering this negative outcome expectation signal by optogenetic stimulation of vHb neurons evoked place avoidance behavior. Thus, vHb-MR circuit is essential for representing the level of expected danger and behavioral programming to adaptively avoid potential hazard.


Asunto(s)
Reacción de Prevención/fisiología , Habénula/fisiología , Vías Nerviosas/fisiología , Núcleos del Rafe/fisiología , Neuronas Serotoninérgicas/fisiología , 5,7-Dihidroxitriptamina/metabolismo , Potenciales de Acción/fisiología , Adaptación Psicológica/fisiología , Animales , Animales Modificados Genéticamente , Condicionamiento Clásico/fisiología , Señales (Psicología) , Miedo/fisiología , Habénula/citología , Proteínas Luminiscentes/genética , Proteínas Luminiscentes/metabolismo , Masculino , Neurotransmisores/metabolismo , Núcleos del Rafe/citología , Serotonina/metabolismo , Factores de Transcripción/genética , Factores de Transcripción/metabolismo , Proteína 2 de Transporte Vesicular de Glutamato/genética , Proteína 2 de Transporte Vesicular de Glutamato/metabolismo , Pez Cebra , Proteínas de Pez Cebra/genética , Proteínas de Pez Cebra/metabolismo
13.
J Stroke Cerebrovasc Dis ; 23(10): 2540-2546, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-25282185

RESUMEN

BACKGROUND: Advanced glycation end products (AGEs) promote atherosclerosis through binding to their receptor, RAGE. Since soluble RAGE (sRAGE) and endogenous secretory RAGE (esRAGE) may suppress AGEs-RAGE signaling, we examined the usefulness of sRAGE and esRAGE as biomarkers of early-stage atherosclerosis. METHODS: Serum sRAGE and esRAGE levels were measured in 284 subjects with no history of atherothrombotic diseases. The subjects were divided into high-sRAGE and low-sRAGE groups and high-esRAGE and low-esRAGE groups based on respective median values. We investigated the relationships between these parameters and the following factors: number of metabolic components, maximum intima-media thickness of the common carotid artery (IMT Cmax), carotid plaque calcification, and asymptomatic cerebral white matter lesions. RESULTS: The low-sRAGE and low-esRAGE groups exhibited significantly more components of metabolic syndrome than the high-sRAGE and high-esRAGE groups, respectively. IMT Cmax was significantly higher in the low-sRAGE and low-esRAGE groups. Low-sRAGE levels were significantly associated with carotid plaque calcification. Multiple linear regression analysis identified body mass index (BMI), age, and high-sensitivity C-reactive protein as determinants of sRAGE, whereas only BMI was identified as a determinant of esRAGE. CONCLUSIONS: We demonstrated that sRAGE and esRAGE are associated with atherosclerotic risk factors in early-stage atherosclerosis, suggesting that their levels evolve in correlation with those of metabolic components and inflammation. Interestingly, low-sRAGE and esRAGE levels are associated with high IMT Cmax, but only low-sRAGE levels were associated with carotid plaque calcification. Thus, sRAGE and esRAGE may reflect different aspects of atherosclerosis in its early stage.


Asunto(s)
Índice de Masa Corporal , Enfermedades de las Arterias Carótidas/sangre , Arteria Carótida Común/patología , Productos Finales de Glicación Avanzada/sangre , Factores de Edad , Anciano , Biomarcadores/sangre , Proteína C-Reactiva/análisis , Enfermedades de las Arterias Carótidas/patología , Grosor Intima-Media Carotídeo , Estenosis Carotídea/sangre , Estenosis Carotídea/patología , Femenino , Productos Finales de Glicación Avanzada/clasificación , Humanos , Modelos Lineales , Masculino , Síndrome Metabólico/sangre , Síndrome Metabólico/patología , Persona de Mediana Edad , Isoformas de Proteínas , Factores de Riesgo , Calcificación Vascular/sangre , Calcificación Vascular/patología
14.
Neuron ; 78(5): 881-94, 2013 Jun 05.
Artículo en Inglés | MEDLINE | ID: mdl-23684786

RESUMEN

The encoding of long-term associative memories for learned behaviors is a fundamental brain function. Yet, how behavior is stably consolidated and retrieved in the vertebrate cortex is poorly understood. We trained zebrafish in aversive reinforcement learning and measured calcium signals across their entire brain during retrieval of the learned response. A discrete area of dorsal telencephalon that was inactive immediately after training became active the next day. Analysis of the identified area indicated that it was specific and essential for long-term memory retrieval and contained electrophysiological responses entrained to the learning stimulus. When the behavioral rule changed, a rapid spatial shift in the functional map across the telencephalon was observed. These results demonstrate that the retrieval of long-term memories for learned behaviors can be studied at the whole-brain scale in behaving zebrafish in vivo. Moreover, the findings indicate that consolidated memory traces can be rapidly modified during reinforcement learning.


Asunto(s)
Reacción de Prevención/fisiología , Mapeo Encefálico , Encéfalo/fisiología , Recuerdo Mental/fisiología , Potenciales de Acción/genética , Animales , Animales Modificados Genéticamente , Biotina/metabolismo , Encéfalo/citología , Encéfalo/cirugía , Calcio/metabolismo , Señalización del Calcio/genética , Señales (Psicología) , Proteínas ELAV/genética , Proteínas ELAV/metabolismo , Electrólisis , Reacción de Fuga/fisiología , Lateralidad Funcional/genética , Glutamato Descarboxilasa/genética , Glutamato Descarboxilasa/metabolismo , Neuroimagen , Neuronas/fisiología , Parvalbúminas/metabolismo , Técnicas de Placa-Clamp , Natación/fisiología , Factores de Tiempo , Proteínas de Transporte Vesicular de Glutamato/genética , Proteínas de Transporte Vesicular de Glutamato/metabolismo , Pez Cebra
16.
Biochem Biophys Res Commun ; 417(2): 812-6, 2012 Jan 13.
Artículo en Inglés | MEDLINE | ID: mdl-22197809

RESUMEN

The fruit fly, Drosophila melanogaster is an established model used for aging and longevity studies and more recently for sleep studies. Mammals and Drosophila share various physiological, pathological, pharmacological and genetic similarities in these processes. In particular, sleep is essential for survival in both species and both have age-associated sleep quality alterations. Here we report that a high calorie diet, which accelerates the aging process and reduces lifespan across species, also accelerates age-associated sleep changes in Drosophila. These changes are more evident in the dopamine transporter mutant, fumin, that displays a short sleep phenotype due to enhanced dopaminergic signaling. With normal food, fumin mutants sleep for only one third of the time that the control flies do, but still show equivalent longevity. However, when on a mildly high calorie diet, their sleep length shows a marked decrease and they have a reduced longevity. These data indicate that the age-associated change in sleep in Drosophila is a physiologically regulated aging process that is tightly linked to calorie intake and that the dopamine level plays an important role. In addition, this provides another evidence that sleep is essential for the longevity of Drosophila.


Asunto(s)
Restricción Calórica , Drosophila melanogaster/fisiología , Trastornos del Sueño-Vigilia/fisiopatología , Sueño/fisiología , Animales , Proteínas de Transporte de Dopamina a través de la Membrana Plasmática/genética , Proteínas de Drosophila/genética , Drosophila melanogaster/genética , Longevidad/genética , Longevidad/fisiología , Sueño/genética
17.
Biochem Biophys Res Commun ; 417(2): 807-11, 2012 Jan 13.
Artículo en Inglés | MEDLINE | ID: mdl-22197814

RESUMEN

Sleep is a unique behavioral state that is conserved between species, and sleep regulation is closely associated to metabolism and aging. The fruit fly, Drosophila melanogaster has been used to study the molecular mechanism underlying these physiological processes. Here we show that the c-Jun N-terminal Kinase (JNK) gene, known as basket (bsk) in Drosophila, functions in neurons to regulate both sleep and longevity in Drosophila. Pan-neuronal knockdown of JNK mRNA expression by RNA interference resulted in a decrease in both sleep and longevity. A heterozygous knockout of JNK showed similar effects, indicating the molecular specificity. The JNK knockdown showed a normal arousal threshold and sleep rebound, suggesting that the basic sleep mechanism was not affected. JNK is known to be involved in the insulin pathway, which regulates metabolism and longevity. A JNK knockdown in insulin-producing neurons in the pars intercerebralis had slight effects on sleep. However, knocking down JNK in the mushroom body had a significant effect on sleep. These data suggest a unique sleep regulating pathway for JNK.


Asunto(s)
Drosophila melanogaster/fisiología , Proteínas Quinasas JNK Activadas por Mitógenos/genética , Longevidad/genética , Neuronas/enzimología , Sueño/genética , Animales , Drosophila melanogaster/enzimología , Drosophila melanogaster/genética , Técnicas de Silenciamiento del Gen , Interferencia de ARN
18.
Brain Nerve ; 62(12): 1269-75, 2010 Dec.
Artículo en Japonés | MEDLINE | ID: mdl-21139179

RESUMEN

Carotid stenosis is an important cause of atherothrombotic cerebral infarction. Moreover, it reflects the severity of systemic atherosclerosis and is a useful predictor of cardiovascular events. Atherosclerotic changes often develop at the site of carotid bifurcation, where shear stress can easily induce endothelial cell damage. The extent of this damage depends on various risk factors such as hypertension, dyslipidemia, and diabetes mellitus. Endothelial cell dysfunction induces the accumulation of inflammatory cells, migration and proliferation of smooth muscle cells, and release of various cytokines and chemokines, which cause carotid plaques and stenosis. Carotid plaques consist of a lipid core with infiltration inflammatory cells covered with a fibrous cap. Cerebral infarction occurs as a result of rupture and thrombus formation on the surface of the carotid plaque by thromboembolic and hemodynamic mechanisms. Rupture-prone carotid plaques are called vulnerable or unstable plaques. The characteristics of vulnerable plaques are active inflammation, with extensive macrophage accumulation, a thin cap with a large lipid core, endothelial denudation with superficial platelet aggregation, fissures, and severe stenosis. To assess the risk of cardiovascular events, it is important to identify vulnerable plaques by imaging techniques and novel assays such as the high-sensitivity C-reactive protein assay. In patients at a high risk of developing cerebral infarction, carotid endoarterectomy or stenting with the best medical treatment is useful in reducing cerebrovascular events.


Asunto(s)
Estenosis Carotídea/etiología , Infarto Cerebral/etiología , Infarto Cerebral/prevención & control , Biomarcadores/sangre , Proteína C-Reactiva/análisis , Estenosis Carotídea/diagnóstico , Estenosis Carotídea/terapia , Quimiocinas , Citocinas , Diabetes Mellitus , Diagnóstico por Imagen , Dislipidemias , Endarterectomía Carotidea , Humanos , Hipertensión , Factores de Riesgo , Stents
19.
Thromb Res ; 119(4): 511-6, 2007.
Artículo en Inglés | MEDLINE | ID: mdl-17046050

RESUMEN

INTRODUCTION: The Cilostazol Stroke Prevention Study found that cilostazol, a phosphodiesterase 3 inhibitor, can reduce the risk of subsequent stroke in Japanese patients with cerebral infarction. Here, we measured the effects of cilostazol in vitro on shear-induced platelet aggregation, an important mechanism of thrombosis at arterial bifurcations or stenotic lesions. We also evaluated the influences of intrinsic adenosine on the ability of cilostazol to inhibit shear-induced platelet aggregation by investigating the effect of dipyridamole, an inhibitor of cellular adenosine reuptake, in combination with cilostazol in vitro. MATERIALS AND METHODS: We measured platelet aggregation induced by a shear rate of 10,800 s(-1) in whole blood and in platelet-rich plasma from healthy volunteers using a cone-plate streaming chamber. RESULTS: Both cilostazol and adenosine dose-dependently inhibited shear-induced platelet aggregation in platelet-rich plasma samples. Adding a low concentration of adenosine (0.3 microM) did not inhibit shear-induced platelet aggregation, but significantly enhanced the inhibitory effect of cilostazol in platelet-rich plasma. Dipyridamole dose-dependently inhibited shear-induced platelet aggregation in whole blood and significantly enhanced the inhibitory effect of cilostazol on shear-induced platelet aggregation, but did not affect shear-induced platelet aggregation in platelet-rich plasma. The inhibitory effects of cilostazol combined with dipyridamole in whole blood were almost completely reversed by adenosine deaminase. CONCLUSIONS: Dipyridamole appears to synergistically enhance the inhibitory effect of cilostazol on shear-induced platelet aggregation by maintaining high plasma levels of adenosine.


Asunto(s)
Adenosina/farmacología , Dipiridamol/farmacología , Inhibidores de Agregación Plaquetaria/farmacología , Agregación Plaquetaria/efectos de los fármacos , Agregación Plaquetaria/fisiología , Tetrazoles/farmacología , Adenosina/sangre , Adulto , Cilostazol , Dipiridamol/sangre , Sinergismo Farmacológico , Humanos , Masculino , Resistencia al Corte , Tetrazoles/sangre
20.
Cerebrovasc Dis ; 21 Suppl 1: 7-16, 2006.
Artículo en Inglés | MEDLINE | ID: mdl-16479097

RESUMEN

Antiplatelet therapy is indicated for secondary prevention of ischaemic stroke. The first-line antiplatelet agent is aspirin. The effect of aspirin is, however, very limited, and this limited effect of aspirin is argued with termed 'aspirin resistance'. Strategies against aspirin resistance may include alternative use of other antiplatelet agents, combination of aspirin with other antiplatelet agents and investigation into molecular targets to develop novel antiplatelet agents. Progress in antiplatelet therapy should be directed at further reducing the risk of ischaemic events including ischaemic stroke without increasing the risk of haemorrhagic events including haemorrhagic stroke.


Asunto(s)
Inhibidores de Agregación Plaquetaria/uso terapéutico , Accidente Cerebrovascular/prevención & control , Aspirina/efectos adversos , Aspirina/uso terapéutico , Plaquetas/efectos de los fármacos , Cilostazol , Clopidogrel , Diseño de Fármacos , Resistencia a Medicamentos , Quimioterapia Combinada , Hemorragia/etiología , Humanos , Inhibidores de Agregación Plaquetaria/efectos adversos , Ensayos Clínicos Controlados Aleatorios como Asunto , Tetrazoles/efectos adversos , Tetrazoles/uso terapéutico , Ticlopidina/efectos adversos , Ticlopidina/análogos & derivados , Ticlopidina/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...